zika
viru
zikv
repres
latest
seri
viral
pathogen
recent
emerg
becom
global
healthcar
problem
inde
span
entir
histori
humankind
current
day
viral
pathogen
constitut
enorm
socioeconom
burden
virus
high
associ
mortal
rate
case
ebola
viru
middl
east
respiratori
syndrom
mer
sever
acut
respiratori
syndrom
sar
virus
repres
major
caus
morbid
pathogen
greatest
burden
contain
limit
spread
viru
success
medicin
chemistri
design
antivir
agent
becom
sound
current
antivir
drug
categor
function
group
approv
treatment
human
immunodefici
viru
type
herp
simplex
virus
hsv
type
influenza
varicella
zoster
hepat
b
c
papilloma
respiratori
syncyti
howev
major
virus
treatment
option
exist
addit
convent
paradigm
insuffici
address
challeng
emerg
medicin
chemistri
usual
lag
behind
develop
medic
pathogen
becom
problem
come
stark
contrast
antibacteri
treatment
specif
power
due
avail
antibiot
broad
antibacteri
activ
antivir
agent
may
promis
prospect
prophylact
therapeut
set
exampl
sever
virus
includ
zikv
transmit
via
sexual
singl
antivir
agent
appli
topic
onto
mucosa
would
protect
pathogen
inde
condom
contain
lubric
activ
alreadi
promis
strategi
antivir
block
first
step
viral
life
entri
viru
target
cell
pathogen
virus
surround
lipid
bilay
harbor
viral
glycoprotein
mediat
first
unspecif
interact
ubiquit
cell
surfac
structur
eg
glycosaminoglycan
upon
engag
specif
receptor
molecul
conform
chang
glycoprotein
trigger
fusion
viral
cellular
membran
ultim
lead
infect
viral
adsorpt
modul
charg
polymer
agent
polycation
macromolecul
protamin
diethylaminoethyl
peptid
bridg
electrostat
repuls
neg
charg
viral
cellular
membran
therebi
increas
rate
virion
attach
infect
class
posit
charg
polym
wide
use
transduct
enhanc
boost
retrovir
gene
notabl
except
polyethyleneimin
cation
polym
reveal
antivir
effect
derivat
hydrophob
alkyl
side
turn
polyanion
polym
repres
largest
class
materi
block
viral
adsorpt
infect
alreadi
acid
pmaa
shown
suppress
infect
envelop
vesicular
stomat
sindbi
vaccinia
past
decad
especi
advent
acquir
immun
defici
syndrom
aid
pandem
sever
addit
polyanion
polym
describ
antivir
activ
among
sulphat
polysaccharid
sulphat
polym
polyphosph
carbosilan
dendrim
nucleic
acid
polym
inhibit
varieti
envelop
virus
includ
influenza
mechan
underli
viru
inhibit
often
direct
interact
polyanion
viral
glycoprotein
therebi
prevent
receptor
engag
mode
action
bind
polym
cellular
receptor
intracellular
inhibit
viral
suppress
viral
broad
antivir
activ
render
polyanion
polym
interest
candid
prevent
applic
howev
distinct
understand
relationship
class
antivir
miss
work
specif
fill
gap
conduct
systemat
variat
polym
structur
understand
aspect
polym
composit
pivot
inhibitori
antivir
activ
divers
viral
pathogen
specif
aim
studi
identifi
lead
polym
broadest
spectrum
antivir
activ
major
exist
emerg
viral
pathogen
observ
respons
characterist
achiev
synthes
librari
carboxyl
phosphatephosphon
sulfon
polym
differ
anion
function
hydrophob
novel
polym
appli
panel
major
viral
pathogen
ie
well
pseudoparticl
mimic
infect
influenza
rabi
lyssa
sar
lassa
marburg
ebola
virus
major
focu
set
zikv
current
drug
vaccin
exist
identifi
lead
candid
also
viru
specif
antivir
activ
result
provid
clear
suggest
view
make
viru
suscept
inhibit
independ
detail
analysi
structur
characterist
polym
make
superior
inhibitor
viral
infect
anticip
result
studi
prove
use
subsequ
develop
microbicid
activ
current
pathogen
design
polym
divers
function
perform
use
control
polymer
techniqu
name
revers
addit
fragment
chain
transfer
raft
techniqu
highli
toler
presenc
function
group
specif
anion
polymer
mixtur
consequ
accommod
wide
varieti
monom
aspect
deem
pivot
ensur
synthesi
polym
widest
possibl
divers
term
chemic
composit
consid
polym
anion
function
categor
carboxyl
ii
phosphat
phosphon
iii
sulfon
chemic
divers
commerci
avail
meth
acryl
meth
acrylamid
rather
limit
eight
monom
readili
avail
commerci
sourc
led
us
design
six
addit
monom
knowledg
two
phosphatephosphon
monom
phosphat
aep
phosphon
acid
apa
correspond
polym
paep
papa
respect
figur
never
report
methacrylamid
counterpart
phosphat
mep
phosphon
acid
mpa
correspond
polym
pmep
pmpa
respect
figur
report
previous
use
control
polymer
monom
commerci
avail
de
novo
synthes
avail
start
materi
ethylacryl
acid
eaa
propylacryl
acid
paa
avail
commerci
small
amount
monom
synthes
synthes
uncompl
purif
good
yield
make
possibl
obtain
larg
quantiti
requir
polym
synthesi
overal
librari
polyanion
synthes
herein
contain
five
polym
four
polym
five
neg
charg
macromolecul
figur
carboxyl
abl
accomplish
design
strategi
common
small
molecul
medicin
chemistri
thu
row
polym
acryl
methacryl
ethylacryl
propylacryl
polyacid
analog
maintain
polyanion
increas
acid
dissoci
homolog
gradual
increas
length
aliphat
side
chain
hydrophob
polym
addit
hydrophob
group
common
approach
medicin
chemistri
increas
affin
small
molecul
drug
nomin
proteinac
howev
methodolog
hardli
appli
probe
relationship
polym
biomedicin
note
polymer
requir
tediou
optim
regard
choic
raft
agent
choic
solvent
reaction
time
purif
approach
reason
result
polym
perfectli
match
molar
mass
degre
polymer
devoid
regret
variat
molar
mass
dispers
valu
list
tabl
experiment
section
work
therefor
focu
relationship
regard
natur
anion
charg
hydrophob
polym
assum
molar
mass
effect
secondari
chemistri
proven
case
number
recent
high
throughput
optim
evalu
antivir
effect
exert
synthes
polym
first
test
viral
pathogen
repres
recent
viral
pandem
name
zikv
conduct
two
type
experi
herein
term
cell
treatment
viru
treatment
cell
treatment
set
uninfect
target
cell
incub
polym
prior
viral
challeng
identifi
lead
inhibit
viral
infect
activ
complex
cell
cultur
medium
contain
fetal
calf
serum
virion
treatment
approach
polym
preincub
viru
allow
direct
interact
polym
mixtur
ad
target
cell
result
dilut
polym
approach
allow
identifi
compound
directli
interfer
viral
infect
may
use
topic
filtrat
devic
biomedicin
biotechnolog
inactiv
cell
treatment
approach
vero
cell
incub
min
mg
polym
infect
african
zikv
infect
rate
determin
three
day
later
use
bromid
mtt
colorimetr
assay
quantifi
viral
induc
cytopath
result
screen
illustr
somewhat
unexpectedli
overal
major
polym
even
highest
concentr
ineffect
zikv
figur
howev
two
polym
poli
vinylbenzo
acid
pvbza
poli
vinylbenzenesulfon
psvb
reveal
activ
share
structur
similar
rather
hydrophob
styren
polym
data
provid
earli
indic
natur
anion
charg
carboxyl
phosphatephosphon
sulfon
decis
observ
antivir
activ
polym
instead
hydrophob
polym
backbon
appear
contribut
significantli
microbicid
activ
polyanion
viru
treatment
condit
virion
first
expos
mg
polym
min
mixtur
use
inocul
cell
result
tenfold
dilut
polym
highest
cell
cultur
concentr
mg
zikv
infect
quantifi
describ
mtt
experi
confirm
activ
pvbza
psvb
figur
reveal
poli
ethylacryl
acid
peaa
anoth
lead
polym
direct
antivir
activ
peaa
structur
similar
pvbza
psvb
also
hydrophob
backbon
interestingli
poli
propylacryl
acid
ppaa
hydrophob
backbon
emphas
addit
methylen
group
monom
unit
compar
peaa
reveal
antivir
activ
thu
row
carboxyl
polym
paa
pmaa
peaa
ppaa
appear
optim
hydrophob
compon
peaa
endow
polym
enhanc
activ
effect
exert
three
lead
compound
corrobor
quantit
measur
intracellular
level
viral
e
protein
use
immunodetect
shown
figur
b
pvbza
psvb
inhibit
zikv
infect
cell
virion
treatment
condit
inhibitori
concentr
psvb
mg
cell
treatment
assay
mg
expos
viru
demonstr
direct
effect
virion
pvbza
markedli
less
activ
peaa
activ
viru
mg
figur
b
note
none
test
polym
toxic
concentr
test
figur
thu
polym
studi
work
three
lead
composit
suppress
infect
vero
cell
zikv
close
examin
antivir
effect
lead
polym
individu
cell
basi
confoc
laser
scan
microscopi
perform
use
experiment
setup
describ
upon
infect
cell
fix
stain
zikv
e
protein
nuclei
cytoskeleton
figur
exposur
cell
mg
psvb
entir
prevent
zikv
infect
figur
stain
pattern
intens
nuclei
cytoskeleton
actin
mg
unaffect
figur
confirm
lack
cytotox
polym
pvbza
also
suppress
zikv
infect
less
activ
psvb
figur
merg
imag
shown
control
see
figur
support
inform
confirm
result
figur
b
corrobor
peaa
show
antivir
activ
virion
treatment
assay
without
sign
cytotox
figur
figur
support
inform
visual
possibl
interact
polym
virion
b
copolym
synthes
shown
figur
support
inform
fluoresc
polym
block
zikv
infect
absenc
cell
viru
label
macromolecul
alon
show
fluoresc
structur
indic
homogen
distribut
polym
solut
figur
howev
presenc
viral
particl
fluoresc
microscop
aggreg
size
becam
visibl
figur
disappear
viru
inoculum
serial
dilut
figur
format
peaazikv
aggreg
confirm
flow
cytometri
use
peaa
figur
support
inform
data
illustr
coagul
viral
particl
peaa
strongli
support
notion
inhibitori
activ
polym
due
direct
contact
macromolecul
viru
experi
far
perform
wide
use
african
zikv
strain
readili
analyz
vero
close
mimic
physiolog
condit
perform
experi
two
clinic
relev
zikv
isol
hela
human
cervic
carcinoma
cell
line
isol
zikv
deriv
brain
abort
fetu
obtain
serum
infect
patient
puerto
rico
obtain
center
diseas
control
cdc
prevent
summar
figur
detail
figur
support
inform
psvb
pvbza
cell
treatment
peaa
virion
treatment
almost
entir
inhibit
infect
hela
cell
isol
concentr
mg
architectur
nucleu
cytoskeleton
unaffect
three
polym
indic
lack
cytotox
thu
specif
inhibit
zikv
infect
figur
figur
support
inform
next
investig
identifi
relationship
similar
viral
pathogen
first
exclud
cytotox
effect
polym
may
interfer
interpret
result
deriv
antivir
assay
test
panel
mammalian
cell
use
host
divers
pathogen
studi
hela
deriv
bhk
elvi
cell
hepat
vero
cell
remain
virus
toxic
polyanion
quantifi
cell
mg
concentr
polym
elvi
mg
vero
cell
highest
concentr
polym
use
respect
experi
toxic
screen
mtt
assay
reveal
decreas
metabol
activ
cell
upon
incub
polym
margin
figur
support
inform
account
antivir
effect
describ
inhibitori
activ
polym
test
infect
use
cell
express
upon
viral
stark
contrast
data
obtain
zikv
figur
polyanion
suppress
infect
level
cell
viru
treatment
condit
figur
figur
support
inform
valu
indic
similar
zikv
viru
treatment
typic
superior
cell
treatment
promin
poli
acryl
pspa
poli
acid
pamp
tabl
observ
reiter
polyanion
antivir
activ
polym
character
higher
potenc
polym
allow
come
contact
viral
particl
prior
administ
onto
cell
appear
strength
polyanion
known
polyelectrolyt
decis
polym
potent
valu
viru
treatment
order
tabl
note
polyanion
polym
heparin
dextran
sulfat
polyphosph
carbosilan
dendrim
less
potent
inhibitor
valu
high
low
mg
par
polysulfon
carboxyl
paa
especi
pmaa
also
highli
potent
contrast
peaa
ppaa
two
polym
significantli
higher
pka
pk
vs
paa
henc
markedli
lower
ioniz
physiolog
ph
significantli
less
activ
valu
mg
moreov
three
hydrophob
lead
identifi
zikv
treatment
rather
inferior
inhibitor
case
therefor
hydrophob
polym
appear
strong
contribut
factor
overal
inhibitori
effect
polym
case
zikv
antivir
activ
polyanion
test
elvi
cell
contain
hsv
induc
gene
express
upon
infect
via
viral
transactiv
report
enzym
activ
quantifi
h
post
infect
viral
induc
cytopath
effect
occur
shown
figur
viru
treatment
figur
support
inform
cell
treatment
experi
exposur
viru
polym
prior
administr
cell
result
higher
antivir
effect
valu
viru
treatment
lower
cell
treatment
tabl
polysulfon
reveal
potenc
low
mg
pspa
viru
treatment
setup
sub
mg
potenc
pamp
cell
treatment
setup
potent
carboxyl
valu
mg
pmaa
viru
treatment
although
valu
nearli
higher
cell
treatment
approach
polym
valu
exceed
rang
concentr
test
experi
result
fulli
corrobor
plaqu
reduct
assay
allow
assess
effect
antivir
spread
viral
infect
figur
support
inform
viral
prolifer
within
confluent
cultur
vero
cell
lead
format
viru
induc
plaqu
wherea
inhibit
viral
prolifer
afford
pictur
devoid
plaqu
confirm
find
list
observ
polyanion
differ
greatli
antivir
activ
polyanion
prove
highli
potent
inhibitor
contrast
polym
reveal
minor
rather
insignific
activ
among
carboxyl
polym
highest
anion
charact
paa
exhibit
virtual
activ
benzyl
pvbza
methacryl
pmaa
prove
strongest
inhibitor
among
polym
next
determin
effect
polym
influenza
panel
virus
current
antivir
therapi
exist
gener
lentivir
pseudoparticl
encod
luciferas
pseudotyp
glycoprotein
lyssa
rabi
viru
two
neurotrop
rhabdovirus
caus
rabi
human
anim
ebola
marburg
viru
belong
famili
filovirus
respons
sporad
outbreak
fatal
hemorrhag
fever
africa
sar
coronaviru
caus
sar
epidem
lassa
viru
arenaviru
caus
lassa
fever
addit
polym
analyz
inhibit
human
adenoviru
type
nonenvelop
viru
clinic
relev
immunosuppress
transplant
shown
figur
figur
support
inform
none
polym
led
mark
inhibit
adenoviru
infect
wherea
test
pseudoparticl
except
influenza
inhibit
least
two
polym
overal
result
inhibitori
activ
polym
see
figur
import
observ
screen
standard
strong
polyelectrolyt
pamp
highli
ioniz
paa
reveal
broad
antivir
activ
neg
charg
alon
make
polym
strong
antivir
agent
illustr
inhibitori
activ
poli
phosphatesphosphon
viral
particl
inhibitori
effect
polym
minim
nonexist
surpris
except
conclus
poli
vinylphosphon
acid
pvpa
prove
highli
effect
marburg
sar
influenza
viru
particularli
sar
figur
influenza
pvpa
prove
effect
polyanion
test
work
among
polym
styren
psvb
appear
strongest
lead
effect
inhibitor
rang
polym
pseudotyp
viral
particl
figur
similarli
pvbza
appear
strongest
lead
among
carboxyl
case
hydrophob
peaa
also
good
lead
particularli
effect
filovirus
ebola
marburg
taken
togeth
data
screen
strongli
support
notion
combin
anion
charg
hydrophob
polym
backbon
necessari
combin
make
effect
broadli
act
antivir
polym
specif
novelti
work
lie
consid
polyanion
antivir
agent
zikv
pathogen
analysi
polym
activ
identifi
two
carboxyl
peaa
pvbza
polysulfon
psvb
latter
potent
inhibit
clinic
relev
zikv
strain
physiolog
relev
cell
type
valu
mg
rang
without
caus
cytotox
effect
come
contrast
recent
report
two
prototyp
polyanion
dextran
sulfat
heparin
shown
exert
margin
antivir
activ
carboxyl
peaa
provid
evid
direct
interact
virion
demonstr
identifi
lead
polym
inhibit
zikv
differ
mechan
promis
ad
hoc
applic
polym
use
topic
microbicid
well
establish
besid
mosquito
zikv
also
transmit
via
sexual
sexual
transmiss
also
result
zikv
potenti
microcephali
brain
malform
vagin
appli
microbicid
may
help
protect
woman
risk
acquir
zikv
sexual
transmit
virus
thu
anim
studi
analyz
effect
peaa
pvbza
psvb
prevent
vagin
zikv
infect
mice
model
highli
warrant
standpoint
relationship
virus
data
suggest
inhibit
polym
relat
presenc
densiti
viral
glycoprotein
embed
viral
envelop
inde
nonenvelop
adv
appear
least
suscept
polymer
inhibitor
good
agreement
prior
observ
zikv
surfac
dens
pack
inhibit
lead
polym
turn
uniqu
incorpor
activ
polym
almost
trivial
observ
nearli
polymer
inhibitor
numer
inhibitor
prior
surfac
intermedi
term
coverag
inde
viru
inhibit
greater
number
polym
screen
compar
zikv
fewer
data
indic
lack
envelop
envelop
dens
gp
shield
make
virus
less
suscept
inhibit
polym
contrast
spars
moder
coverag
envelop
viral
particl
make
viru
well
suscept
inhibit
like
due
less
promin
interact
differ
viral
plausibl
interact
lipid
standpoint
relationship
polym
first
import
conclus
work
polysulfon
strong
polyanion
histor
deem
prime
microbicid
make
broad
spectrum
antivir
materi
specif
polym
famili
reveal
notabl
inhibitori
activ
influenza
sar
except
psvb
zikv
anoth
signific
surpris
spectrum
activ
vinyl
pvpa
polyphosphatesphosphon
prove
virtual
devoid
antivir
activ
screen
pvpa
notabl
except
polym
score
well
nearli
pathogen
except
zikv
ebola
reveal
highest
activ
sar
final
notic
find
studi
overal
lead
identifi
herein
name
pvbza
polycarboxyl
hydrophob
backbon
polym
exhibit
superior
compar
polym
activ
viru
use
work
except
nonenvelop
adv
thu
combin
anion
charg
hydrophob
broaden
antivir
activ
polym
pvbza
repres
highli
promis
candid
preclin
studi
microbicid
develop
work
perform
screen
polym
inhibitori
agent
viral
pathogen
provid
clear
suggest
view
make
viru
suscept
inhibit
independ
detail
analysi
structur
characterist
polym
make
superior
broad
inhibitor
viral
infect
show
envelop
virus
least
one
polym
found
antivir
inhibit
viral
infect
rather
univers
phenomenon
specif
novelti
work
lie
consider
polyanion
antivir
agent
zikv
sar
ebola
pathogen
caus
recent
pandem
novelti
implement
methodolog
classic
medicin
chemistri
systemat
variat
extens
structur
design
macromolecular
drug
believ
aspect
allow
us
identifi
lead
rather
unexpect
consid
overal
context
macromolecular
antivir
agent
specif
data
strongli
suggest
hydrophob
polym
backbon
pivot
antivir
activ
macromolecul
overal
lead
studi
poli
vinylbenzo
acid
pvbza
suppress
infect
envelop
virus
studi
work
identifi
lead
promis
candid
microbicid
could
formul
antivir
gel
spray
paint
coat
divers
biomed
biotechnolog
futur
work
identifi
lead
polym
focu
three
aspect
clarifi
whether
identifi
lead
prevent
zikv
infect
via
vagin
challeng
mice
model
evalu
potenti
microbicid
develop
clarifi
detail
mechan
antivir
activ
polym
identifi
viral
envelop
glycoprotein
caus
essenti
contact
aim
optim
antivir
effect
lead
polym
achiev
higher
efficaci
antivir
treatment
specif
variat
polym
polym
branch
hyperbranch
dendrit
backbon
star
polym
unless
state
otherwis
reagent
purchas
use
without
purif
monom
synthesi
mpa
apa
mep
aep
eaa
paa
synthes
describ
detail
support
inform
polym
synthesi
polym
synthes
via
raft
polymer
techniqu
use
azobisisobutyronitril
aibn
valeronitril
acid
acva
initi
cyanomethyl
dodecyl
trithiocarbon
cdtc
dodecylsulfanylthiocarbonyl
sulfanyl
pentano
acid
cdpa
cyanomethyl
methyl
phenyl
cmpd
dodecylthiocarbonothioylthio
acid
dcma
phenylcarbonothioylthio
pentano
acid
cppa
raft
agent
dimethylformamid
solvent
describ
detail
support
inform
follow
initi
raft
agent
combin
use
synthes
polym
paa
aibn
cdtc
pmaa
aibn
cdpd
peaa
cdpa
ppaa
cdpa
pvbz
aibn
cmdp
pvsa
aibn
cmpd
pspa
aibn
dcma
pamp
aibn
dcma
psvb
aibn
dcma
pvpa
cmpd
pmpa
acva
cppa
papa
cdpa
pmep
cdpa
paep
cdpa
polym
analysi
chromatographi
perform
use
system
compris
shimadzu
hplc
pump
shimadzu
refract
index
detector
dawn
heleo
light
scatter
detector
along
pda
detector
equip
either
linear
column
particl
length
mm
intern
diamet
mm
seri
ohpak
hq
shodex
column
dimens
mm
particl
size
b
sdplu
linear
column
particl
length
mm
intern
diamet
mm
provid
effect
molecular
weight
rang
solvent
use
either
pb
filter
filter
ppm
sodium
azid
b
dimethylformamid
dmf
libr
ad
dndc
use
calcul
molecular
weight
polym
determin
assum
full
mass
recoveri
result
polym
character
present
support
inform
cell
viabil
access
cell
viabil
appli
cell
line
cell
elvi
cell
cell
cell
vero
cell
seed
plate
incub
highest
polym
concentr
use
respect
assay
incub
medium
discard
mg
bromid
solut
ad
cell
live
cell
reduc
yellow
mtt
salt
nad
p
oxidoreductas
system
caus
format
insolubl
purpl
formazan
crystal
h
supernat
discard
formazan
crystal
dissolv
dimethylsulfoxid
dmso
ethanol
absorpt
detect
nm
correct
background
absorpt
nm
effect
polym
zikv
infect
initi
screen
perform
colorimetr
detect
vero
cell
cultur
dulbecco
modifi
essenti
medium
dmem
supplement
vv
fetal
calf
serum
fc
sodium
pyruv
nonessenti
amino
acid
sigma
unit
penicillin
streptomycin
vero
cell
seed
well
plate
next
day
polym
ad
triplic
cell
cell
treatment
incub
min
cell
infect
zikv
strain
zikv
strain
isol
sentinel
rhesu
viru
treatment
set
polym
mg
preincub
viru
zikv
min
use
mixtur
infect
cell
triplic
post
infect
mtt
ad
cell
formazan
crystal
form
live
cell
measur
describ
use
indirectli
detect
zikv
induc
cell
death
assess
protect
polyanion
effect
polym
reassess
concentr
zikv
immunodetect
assay
cell
viru
treatment
experi
perform
describ
h
post
infect
cell
rins
pb
fix
min
room
temperatur
paraformaldehyd
permeabil
cold
methanol
min
wash
pb
next
cell
incub
mous
antiflaviviru
antibodi
pb
contain
vv
fc
vv
h
follow
time
time
wash
pb
contain
vv
cell
incub
horseradish
peroxidas
hrp
antibodi
h
next
cell
wash
four
time
tetramethylbenzidin
tmb
substrat
ad
min
incub
room
temperatur
reaction
stop
sulfur
acid
absorpt
measur
nm
baselin
correct
nm
use
elisa
micropl
reader
visual
zikv
infect
laser
scan
microscopi
perform
vero
cell
seed
ibidi
slide
next
day
cell
incub
psvb
pvbza
infect
min
incub
zikv
cell
treatment
viru
treatment
zikv
incub
peaa
fluoresc
peaa
rhodamin
b
copolym
b
min
mixtur
use
infect
vero
treatment
post
infect
cell
fix
min
paraformaldehyd
permeabil
afterward
block
solut
contain
vv
fc
vv
bovin
serum
albumin
bsa
use
incub
cell
min
room
temperatur
visual
zikv
infect
mous
antiflaviviru
antibodi
vv
secondari
alexa
flour
goat
igg
molecular
probe
vv
use
antibodi
solut
phosphat
buffer
salin
pb
contain
vv
bsa
incub
cell
min
room
temperatur
next
nucleu
stain
hoechst
thermofish
scientif
vv
afterward
actin
filament
stain
attotec
vv
cell
store
pb
kept
dark
left
microscopi
imag
acquisit
perform
use
zeiss
lsm
zen
softwar
imag
process
analyz
interact
zikv
peaa
differ
zikv
amount
incub
b
ibidi
slide
min
afterward
mixtur
fix
paraformaldehyd
microscopi
imag
acquisit
perform
antivir
activ
polyanion
clinic
zikv
isol
zikv
zikv
fb
deriv
brain
abort
foetu
prvabc
obtain
serum
infect
patient
puerto
rico
obtain
cdc
assess
hela
cell
cultur
dmem
supplement
unit
penicillin
streptomycin
nonessenti
amino
acid
vv
fc
effect
polym
infect
viru
stock
gener
transient
transfect
transfect
overnight
incub
transfect
mixtur
replac
ml
dmem
inactiv
fc
h
cultur
supernat
collect
centrifug
min
g
remov
cell
debri
viru
stock
store
report
cell
line
obtain
nih
arrrp
cultur
dmem
supplement
unit
penicillin
streptomycin
fc
cell
line
stabli
transfect
cassett
express
upon
infect
viral
protein
tat
express
activ
long
termin
repeat
ltr
result
express
viru
treatment
assay
particl
incub
polym
mg
min
mixtur
use
triplic
infect
cell
seed
day
plate
cell
treatment
assay
polym
ad
triplic
cell
cultur
medium
incub
h
cell
infect
infect
rate
determin
post
infect
detect
activ
cellular
lysat
use
report
gene
assay
system
mammalian
cell
thermo
fisher
scientif
orion
ii
micropl
luminomet
berthold
bad
wildbad
germani
report
gene
activ
record
rel
light
unit
per
second
obtain
infect
cell
contain
polyanion
use
control
effect
polym
infect
use
elvi
report
cell
viru
stock
green
fluoresc
protein
gfp
gener
infect
elvi
cell
genet
engin
babi
hamster
kidney
cell
express
upon
infect
h
cultur
supernat
contain
progeni
viru
collect
centrifug
min
g
remov
cell
debri
viru
stock
store
elvi
cell
cultur
dmem
supplement
unit
penicillin
streptomycin
glutamin
fc
dna
bear
hsv
induc
promot
gene
chimer
link
escherichia
coli
lacz
report
gene
hsv
lead
induct
promot
product
lacz
product
use
determin
infect
rate
h
post
infect
detect
activ
cellular
lysat
use
report
gene
assay
system
mammalian
cell
thermo
fisher
scientif
orion
ii
micropl
luminomet
berthold
bad
wildbad
germani
valu
repres
report
gene
activ
rel
light
unit
per
second
rlu
deriv
triplic
infect
minu
background
activ
deriv
uninfect
cell
shown
percent
infect
rate
rel
untreat
infect
control
viru
treatment
assay
incub
polym
mg
min
mixtur
use
triplic
infect
elvi
cell
seed
day
plate
cell
treatment
assay
mg
polym
ad
triplic
cell
cultur
medium
incub
h
cell
infect
effect
polym
infect
use
vero
cell
strain
produc
infect
vero
cell
harvest
supernat
h
later
supernat
centrifug
g
min
viru
stock
store
vero
cell
cultur
dmem
lonza
basel
switzerland
contain
fc
u
penicillin
streptomycin
invitrogen
glostrup
denmark
inhibit
determin
viru
treatment
assay
cell
seed
plate
densiti
cell
per
well
cultur
overnight
overnight
cultur
media
replac
fresh
one
viru
titer
pfu
incub
drug
initi
concentr
mg
min
bench
ad
cell
final
concentr
drug
mg
viral
titer
pfu
h
later
standard
plaqu
assay
perform
briefli
media
remov
cell
fix
paraformaldehyd
pfa
solut
min
subsequ
cell
wash
twice
pb
solut
crystal
violet
pb
contain
ethanol
use
stain
cell
min
stain
wash
away
pb
plaqu
enumer
microscop
number
plaqu
normal
control
sampl
infect
present
percentag
control
effect
polym
pseudoparticl
cell
cultur
dmem
supplement
unit
penicillin
streptomycin
fc
cell
kindli
provid
germani
cultur
dmem
supplement
unit
penicillin
streptomycin
nonessenti
amino
acid
sigma
fc
lentivir
pseudotyp
harbour
glycoprotein
influenza
lyssa
rabi
ebola
marburg
sar
lassa
viru
obtain
via
cotransfect
cell
cell
seed
format
crippl
lentivir
vector
encod
firefli
luciferas
lack
larg
part
env
gene
express
plasmid
respect
viral
glycoprotein
describ
influenza
lyssa
ebola
pseudotyp
harvest
later
aliquot
store
cell
influenza
pseudoparticl
cell
lyssa
rabi
ebola
sar
pseudotyp
lentivirus
vero
cell
lassa
pseudoparticl
seed
day
infect
plate
next
treat
polym
h
cell
infect
respect
pseudoparticl
infect
rate
determin
quantifi
firefli
luciferas
activ
cellular
lysat
use
luciferas
assay
system
promega
madison
usa
valu
repres
infect
rate
rel
control
infect
contain
polyanion
report
gene
activ
rel
light
unit
per
second
rlu
deriv
triplic
infect
minu
background
activ
deriv
uninfect
cell
effect
polym
human
adenoviru
infect
human
adenoviru
type
vector
contain
human
cytomegaloviru
hcmv
enhanc
green
fluoresc
protein
egfp
express
cassett
produc
purifi
one
discontinu
one
continu
cscl
densiti
gradient
subsequ
chromatographi
dispos
amersham
physic
particl
titer
determin
particl
lysi
confirm
assess
effect
polym
viru
infect
vector
titrat
mg
polym
incub
min
prior
infect
cell
cultiv
mem
supplement
fc
unit
penicillin
streptomycin
per
well
seed
format
duplic
infect
perform
multipl
infect
moi
pretreat
viru
egfp
express
analyz
use
gallio
flow
cytomet
post
transduct
viru
inhibit
data
analys
viral
inhibit
data
express
valu
rel
level
infect
noninhibit
sampl
cell
viru
report
mean
standard
error
deriv
two
independ
experi
perform
triplic
datapoint
author
declar
conflict
interest
